"Weight Gain, Blood Pressure Rise Seen With JAK Inhibitor Therapy" - Megan Brooks
Pharmacologic inhibition of Janus kinases (JAK) 1 and 2 is associated with significant weight gain and increased systolic blood pressure, according to a review of patients treated with the JAK1/2 inhibitor ruxolitinib. "We recommend that patients who go on this medication and do have an increase in weight get a full metabolic workup," said Emily Gallagher, MD, assistant professor of medicine, endocrinology, diabetes and bone disease at the Icahn School of Medicine at Mount Sinai. "Because cancer today is much more of a chronic disease and patients are surviving longer, we want to make sure we're not putting them at risk for other complications such as cardiovascular disease," said Dr. Gallagher. She presented her research at the Endocrine Society’s annual meeting. "As JAK1 and 2 inhibitors are developed and more widely used, it is important to develop a greater understanding of their long-term metabolic consequences," Dr. Gallagher and colleagues note in their meeting poster.
— Emily Gallagher, MD, Assistant Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press ReleasesMount Sinai Researcher’s Examine the Metabolic Effects of an Oral Blood Cancer Drug
Nov 12, 2019 View All Press Releases